New CEO Revamps Top Team, Specialty Care Business At Sobi
The new CEO of Sweden's rare diseases company sets up an executive team, highlights its specialty business, and forecasts a better 2017 than previously thought.
You may also be interested in...
Swedish specialty pharma and rare diseases company seeks to sustain recent rapid revenues growth with increased R&D focus and investments in its hematology and immunology franchises.
The interferon gamma blocker is the first new therapy for HLH in 24 years. FDA approval came about four months after Sobi acquired global rights from NovImmune in a deal meant to improve the company's growth prospects.
Laura Soucek, one of In Vivo’s 2020 Rising Leaders, is hoping to take Barcelona-based start-up Peptomyc to the next level. The company is nearing the clinic with an inhibitor of the transcription factor Myc, which is involved in the regulation of cellular proliferation, but can also be a driver of cancer.